Who founded Cybrexa, Inc.?

Cybrexa, Inc. was founded by Per Hellsund, Ranjit Bindra, Peter Glazer.

Who are Cybrexa, Inc.'s investors?

Cybrexa, Inc.'s investors include Connecticut Innovations, HighCape Capital.

Cybrexa, Inc.

2 known investors

Find your way into Cybrexa, Inc.

436 people in our graph share verified history with the Cybrexa, Inc. team — schools, employers, funds. One of them is your warm intro.

Anthony Philippakisunlockedknows Ranjit Bindra · together at Yale University (overlapped)

×4knows the team · via Yale School of Medicine

×3knows the team · via Yale University

knows the team · via Modifi Bio

knows the team · via MSKCC

×2knows the team · via Rensselaer Polytechnic Institute

Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.

Biotech Healthtech Medical Devices

Founders & leadership

Per Hellsund inCo-founder, President & CEOPer Hellsund founded and served as CEO of CyVek Inc. from 2008 to 2014, developing a microfluidic assay platform for life sciences and clinical diagnostics before the company was acquired by Bio-Techne for $105 million; prior to that, he was President of inc.jet Inc., an industrial thermal inkjet technology company, and holds undergraduate degrees in mechanical engineering and business as well as a master's degree in management from Rensselaer Polytechnic Institute.

Ranjit Bindra inScientific Co-founder & Chief Scientific AdvisorRanjit Bindra is a physician-scientist at the Yale School of Medicine where he directs the Yale Brain Tumor Center and leads an R01-funded research program on synthetic lethal screening strategies in cancer. He has co-founded multiple biotech companies including Cybrexa Therapeutics, Alphina Therapeutics, Modifi Bio (which was acquired by Merck in 2024), and B3 Therapeutics.

Peter GlazerinScientific Co-founder & Chief Medical Advisor

Investors · 2

Connecticut InnovationsNew Haven · $500K – $2M

HighCape CapitalWestport

Founder mafia

2 people who came through Cybrexa, Inc. went on to found or lead other companies.

Per HellsundCo-founder, President & CEOFounded Cybrexa Holding +1 Ranjit BindraScientific Co-founder & Chief Scientific AdvisorFounded Alphina Therapeutics

Competitors · 3

by search overlap

Exelixis47 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

Bioworld40 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Solu33 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Companies competing with Cybrexa, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2020	$2M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2019	$300K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Cybrexa, Inc. do?: Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
Who founded Cybrexa, Inc.?: Cybrexa, Inc. was founded by Per Hellsund, Ranjit Bindra, Peter Glazer.
Who are Cybrexa, Inc.'s investors?: Cybrexa, Inc.'s investors include Connecticut Innovations, HighCape Capital.